Drugs targeting DNA damage repair (DDR) pathways are exciting new agents in cancer therapy. Many of these drugs exhibit synthetic lethality with defects in DNA repair in cancer cells. For example, ovarian cancers with impaired homologous recombination DNA repair show increased sensitivity to poly-(ADPribose) polymerase (PARP) inhibitors. Understanding the activity of different DNA repair pathways in individual tumors, and the correlations between DNA repair function and drug response, will be critical to patient selection for DNA repair targeted agents. Genomic and functional assays of DNA repair pathway activity are being investigated as potential biomarkers of response to targeted therapies.
Introduction
Normal and cancer cells rely on multiple DNA damage response (DDR) pathways specialized to repair specific forms of DNA damage (Table 1) (1) (2) (3) (4) . Key pathways include base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), homologous recombination repair (HRR), nonhomologous end-joining (NHEJ), and interstrand crosslink repair (ICL). If canonical repair pathways are deficient, or repair is unsuccessful, error-prone alternative pathways may be employed, e.g. alt-NHEJ, single-strand annealing, or translesion synthesis (1) (2) (3) (4) .
DNA repair targeted therapies exploit DNA repair defects in cancer cells to generate synthetic lethality (cell death resulting from simultaneous loss or inhibition of two critical functions; for example, cancer cells defective in one DNA repair pathway rely on alternate repair pathways; inhibition of a second repair pathway then results in cell death, an effect which selectively targets repair-deficient cancer cells (5, 6) ). DNA repair defects vary by cancer type. For example, approximately 50% of ovarian carcinomas (OC) exhibit dysfunctional HRR (7) (8) (9) (10) , colon and endometrial cancers are enriched in MMR defects (11) , bladder cancers have frequent NER mutations (12) , and testicular germ cell tumors may be functionally deficient in NER and other DDR pathways (13, 14) . Many biomarkers for response to DNA repair targeted therapies reflect specific alterations in DDR pathways or genomic signatures resulting from aberrant repair.
Cytotoxic chemotherapies induce particular forms of DNA damage that trigger specific repair pathways. Therefore, cancers with DNA repair deficiencies show increased sensitivity to certain chemotherapeutics. For instance, OC patients with germline BRCA1 or BRCA2 (BRCA1/2) mutations (HRR deficiency) and bladder cancer patients with somatic ERCC2 mutations (NER pathway) are more sensitive to platinum agents (15) likely due to decreased capacity to repair platinum-induced DNA damage. HRR and BER deficiencies sensitize cancer cells to topoisomerase-I inhibitors (e.g. topotecan), Research. on October 24, 2017. © 2016 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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HRR deficiency confers sensitivity to inhibitors of the poly-(ADP-ribose) polymerase (PARP) enzyme, which is vital to several DNA repair pathways including BER and NHEJ. Developing biomarkers of DDR function and correlating DNA repair capacity with sensitivity to targeted agents is critical to optimizing efficacy of targeted DNA repair drugs. In this review, we describe candidate biomarkers of response (and resistance) to DNA repair targeted therapies. Genomic sequencing studies demonstrate frequent DDR alterations in diverse cancers, suggesting that DNA repair targeted agents may be broadly active in cancer therapy and highlighting the need for accurate biomarkers of response (17, 18) .
HRR deficiency assays as biomarkers of PARP inhibitor response
PARP inhibitors (PARPi) are selectively lethal to HRR-deficient cells (19, 20) . Synthetic lethality may be mediated by PARPi impairment of BER, although at least 6 potential mechanisms of action have been suggested including alterations in NHEJ, alternative end-joining, and DNA repair protein recruitment; PARP trapping at the replication fork is particularly significant, generating increased double-strand breaks (DSBs) and dependence upon HRR (10, 21) . Different PARPi's may vary in their specificity for PARP enzymes and PARP trapping activity. Identifying the clinically relevant mechanisms of PARPi activity and resistance will be important to selecting optimal biomarkers. PARPi are used as a single agent, resistance typically develops in months, though occasional sustained responses are observed (24) .
The success of PARPi in patients with germline BRCA1/2 mutations, and clinical trials showing better response rates in cancers with germline and somatic BRCA1/2 mutations than in those without, confirmed that damaging BRCA1/2 mutations (suggesting HRR deficiency) are an important biomarker for PARPi sensitivity (25) . Restoration of HRR function by somatic reversion of germline BRCA1/2 mutations confers platinum and PARPi resistance in OC (26, 27) .
Since sensitivity to platinum and PARPi are both associated with HRR defects, platinum sensitivity has been used as a surrogate for HRR deficiency in OC. However, some platinum-sensitive patients do not respond to PARPi, and trials of PARPi in unselected patients produced responses in a subset of platinum-resistant patients (28) . Hence, platinum and PARPi responsiveness are not always concordant. Variability in DNA repair function may underlie this complexity: NER gene mutations are associated with platinum sensitivity in OC patients and cell lines, but exhibit resistance to PARPi in vitro (29) , and PARPi resistance mechanisms such as loss of TP53BP1 or REV7 may be associated with platinum sensitivity (30, 31) .
Clinically feasible, accurate biomarkers for response and resistance to PARPi are needed.
Numerous assays for HRR deficiency are available, each with advantages and disadvantages (Table 2) , and varying capability to predict PARPi response that must be tested in prospective clinical trials.
Targeted sequencing
Targeted multiplex sequencing can identify germline and somatic mutations in DNA repair genes that result in increased or decreased HRR. While BRCA1/2 mutations are the most prevalent biomarkers in PARPi trials, PARPi responses observed in some BRCA1/2 wildtype patients (28) suggests that alterations in other HRR genes may also confer sensitivity. BROCA is a targeted next-generation sequencing assay, which was used to identify damaging mutations in at least one of 13 HRR genes increasing diagnostic or clinical utility as whole exome and genome sequencing become more prevalent, such as using mutational signatures suggestive of BRCA1/2 mutations to identify PARPi sensitivity.
Large-scale disarray in chromosome structure is common in HRR-deficient cancers and may be quantitated by several assays including: 1) loss of heterozygosity (LOH), patterns of loss of one allele at many sites across the genome, via deletion or copy number neutral LOH; 2) telomeric-allelic imbalance (TAI), allelic imbalance near telomeres; and 3) large-scale state transitions (LST), chromosomal breaks between adjacent regions of ≥ 10 Mb. LOH quantification correlates with platinum response in OC (37) .
TAI scores correlate with platinum response in breast cancer and OC and are associated with BRCA1/2 mutations (38) . LST associates with BRCA1/2 alterations in basal-like breast cancer (39) . The three scores (LOH, TAI, LST) show a strong correlation with each other (40) .
Several HRR deficiency biomarkers using patterns of loss of heterozygosity (LOH) are being tested as potential companion diagnostics in PARPi clinical trials. An LOH assessment using a sequencing assay from Foundation Medicine (Cambridge, MA) was the first to be tested as a prospective biomarker in a PARPi clinical trial. In a trial of rucaparib in recurrent OC, response rates were 75%, 36%, and 16%, respectively, in patients with a) germline and somatic BRCA1/2 mutations, b) high LOH but no BRCA1/2 mutation, and c) low LOH and no BRCA mutation (41) . This suggests LOH can be used as a surrogate for HRR and predict PARPi response, a hypothesis being tested in multiple prospective trials (e.g. Table 1) . Myriad Genetics (Salt Lake City, UT) also developed an HRR deficiency assay based on a combination of LOH, TAI and LST, which predicts response to neoadjuvant platinum in triple negative breast cancer (42); and is testing this assay prospectively in multiple PARPi trials. Presumably, the genomic scars identified by these assays remain detectable even if functional HRR is re-established, e.g. by reversion mutations or epigenetic changes. If true, then LOH profiling might be more predictive of PARPi responsiveness early in the disease course before various resistance mechanisms have accumulated. 
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Gene and protein expression
Gene expression signatures of DDR genes have been described that correlate with outcome and platinum response in ovarian, breast and lung cancers (43) (44) (45) . However, a meta-analysis of expression signatures in OC showed that this approach suffers from poor reproducibility (46) . Alternatively, HRR protein levels or methylation, e.g. by immunohistochemistry, may be useful in revealing dynamic HRR alterations. BRCA1 promoter hypermethylation, which down-regulates BRCA1, may contribute to HRR deficiency, though its clinical significance is uncertain. Reversal of BRCA1 hypermethylation was observed in acquired platinum resistance in OC, suggesting that neoplastic cells may re-express silenced BRCA1 as a resistance mechanism (9). BRCA1 expression is further modulated by microRNAs, altering PARPi sensitivity (47) . Many studies of HRR protein expression have been limited by small numbers or technical issues, with poor reproducibility or results inconsistent with current models of HRR signaling.
Therefore, both gene and protein expression as a biomarker for PARPi or other DNA therapies requires further research and clinical validation (48) .
Functional assays
Functional assays can quantitate DNA repair capacity and may provide the most dynamic, real-time readout of DNA repair, but are clinically hampered by technical challenges such as the need for fresh tissue and a DNA-damaging stimulus (49) . The RAD51 focus formation assay reflects activation of HRR machinery and has been applied to clinical samples. marker of PARPi activity but do not clearly correlate with clinical responses in patients (55) . Similarly, PARP enzyme activity in peripheral blood lymphocytes is a good pharmacodynamic but not predictive biomarker in PARPi clinical trials (56, 57) . In vitro cell line studies showed that HRR deficiency results in hyperactivation of PARP and increased levels of PAR polymers, suggesting that hyperactivated PARP or lower PAR levels may be a marker of PARPi sensitivity or resistance respectively (58, 59) . Clinically, wide variations in PARP activity have been observed among patients, which may limit its utility as a predictive biomarker (60) . Changes in PARylation levels have also been used as pharmacokinetic markers of effective PARPi activity (49) . Assays for replication stress include the DNA fiber assay (61) and replication protein A (RPA) foci. Certain forms of DNA damage (e.g. bulky adducts) result in stalling of replication forks. Emerging evidence suggests that replication fork stabilization may be a mechanism of resistance to platinum and PARPi independent of HR dysfunction; for instance, Fanconi Anemia group D2 protein (FANCD2) and Pax-interacting protein 1 (PAXIP1, PTIP) can stabilize stalled replication forks, enabling bypass of the blockage and cell survival (62) .
These assays represent a wide range of approaches for predicting PARPi response. Selection of optimal, clinically feasible assays awaits validation from clinical trials (Supplementary Table 1 ).
ATM/ATR inhibitors and biomarkers
ATM and ATR kinases are critical components of the early response to DNA damage and activation of cell cycle checkpoints (reviewed in (63-66)). ATM and ATR collaborate with checkpoint proteins Chk2 and Chk1, respectively, to arrest the cell cycle and allow time for DNA repair. Studies suggest that inhibiting ATM and/or ATR may increase sensitivity to DNA damage. This sensitization may be particularly profound in cells with deficient DNA repair or increased replication stress.
ATM, ATR, and dual ATM/ATR inhibitors have been developed, with several in clinical trials ( cancer cells with defective DNA repair to chemotherapy (67) . Clinical trials are underway combining VX-970 with chemotherapy in advanced malignancies. AZD6738 is another selective ATR inhibitor in phase I trials combined with several agents. AZD0156 is an ATM selective inhibitor in a phase I trial in advanced cancer combined with olaparib; several other ATM inhibitors are undergoing preclinical investigation.
Combined ATM/ATR inhibitors are generally less specific, and are not active in clinical trials (reviewed in (66) ).
Several biomarkers for response to ATM or ATR inhibitors have been proposed, though clinical data are limited. Alterations in the target kinases (ATM/ATR) or their protein complexes may confer sensitivity to ATM and/or ATR inhibitors (66, 68) . DDR deficiencies may sensitize to ATM/ATR inhibitors due to increased reliance on DDR checkpoints (68) . Alterations causing increased replication stress may enhance sensitivity to ATM/ATR inhibition, e.g. TP53 mutations, CCNE1 (Cyclin E1) amplifications (69, 70) , and mutations in oncogenic drivers such as RAS and MYC (71, 72) . Alternative lengthening of telomeres (ALT), the maintenance of telomere length through an HRR-based mechanism as an alternative to telomerase, may be a biomarker of hypersensitivity to ATR inhibitors (73) . Loss of ATRX, a chromatin remodeling protein, was associated with increased ALT in most cell lines (73) , and may also predict response to ATR inhibition.
Non-homologous end joining (NHEJ) inhibitors and biomarkers
NHEJ is a second major pathway of DSB repair, along with HRR. Repair pathway choice between NHEJ and HRR is mediated by cell cycle phase (HRR occurs during S phase, while NHEJ can proceed during all phases) and by active mediators of pathway choice such as TP53BP1 which promotes HRR and inhibits NHEJ (4). NHEJ is more error-prone due to its end-processing and re-ligation mechanism resulting in nucleotide loss, versus the conservative recombination of HRR using a normal DNA template to exactly replace the damaged region (1).
Research. 
Inhibitors of several NHEJ proteins have been developed; DNA-PKcs inhibitors are the most clinically advanced (Table 3 ) (reviewed in (74, 75) ). DNA-PKcs is the catalytic subunit of DNA-PK, a phosphatidylinositide 3-kinase (PI3K)-related kinase similar to ATM and ATR. Phosphorylation of substrates by DNA-PK induces recruitment of repair proteins to DSBs and activation of checkpoints (75).
CC-115 is a DNA-PKcs/mTOR inhibitor that has entered clinical trials (76) , and CC-122 is a DNA-PK inhibitor (termed a pleiotropic pathway modifier) in a phase I clinical trial (75). ZSTK474 is an ATPcompetitive inhibitor of PI3K that also inhibits DNA-PK and has been tested in early phase clinical trials (75). NU7026 and NU7441 are selective ATP-competitive inhibitors of DNA-PK undergoing preclinical development (77, 78) . DNA-PK inhibitors sensitize cancer cells to DSB-inducing chemotherapies or radiation in preclinical studies, so combination strategies may be considered; MSC2490484A is a DNA-PK inhibitor being combined with radiation therapy in a phase I trial (Supplementary Table 1 Several other classes of agents are closely linked to DDR, and many show enhanced activity in cells with DDR deficiencies. CDK inhibitors block cyclin-dependent kinases critical to cell cycle progression, thereby impacting DNA repair that occurs during, and depends upon, specific phases of the cell cycle. These include inhibitors of CDK4/6 (e.g. palbociclib, recently FDA approved in metastatic breast cancer), CDK1/2/5/9, and CDK12. CDK12 promotes transcription of large RNAs including many HRR genes; inhibition of CDK12 has also been shown to down-regulate HRR through transcriptional regulation (81, 82) .
The p53 protein is critical to the DNA damage response via numerous functions including activation of DDR, G1/S arrest to allow DNA repair, and apoptotic cell death following irreparable DNA damage. Wee1 inhibitors enhance sensitivity to DNA-damaging agents, preferentially in p53-deficient cells that are more reliant on the G2 checkpoint (83).
Biomarkers for most of these agents are yet to be determined (Table 3) . 
